Masimo Corp Stock Price, News & Analysis

Masimo has issued a statement addressing what it claims are deceptive tactics by Politan to distract from its own shortcomings. The company urges shareholders to support its nominees, Joe Kiani and Christopher Chavez, instead of Politan's picks.

Masimo disputes several assertions by Politan, including the qualifications and independence of Politan's nominees, and claims about Masimo's governance and transactions. The company provides detailed counterpoints, asserting that Politan's candidates are neither independent nor suitably qualified.

Masimo clarifies that all transactions, including IP licensing and consumer separation, are overseen by the Board and follow agreed-upon processes. The company further addresses accusations about CEO travel, employee approval ratings, and handling of subpoenas, emphasizing transparency and proper procedures.

Masimo argues that Politan's failure to deliver viable plans and solutions, especially regarding consumer separation, disqualifies their nominees. They also highlight Politan's alleged misinformation and lack of understanding of Masimo's operations.

In summary, Masimo believes that Politan's actions and claims are detrimental to shareholders and urges a vote for its own nominees to ensure value creation and transparency.

Masimo has issued a letter to its stockholders concerning the 2024 Annual Meeting of Stockholders, emphasizing the importance of voting for their director nominees, Joe Kiani and Christopher Chavez. Masimo highlights Chavez's extensive experience in the medical technology industry and contrasts it with the nominees proposed by Politan, whom they describe as paid and lacking independence. Masimo argues that electing Politan's nominees could jeopardize the company's value and future innovation. The letter seeks to assure stockholders of the qualifications and independence of their nominees, aiming for continued innovation-driven revenue growth.

Masimo (NASDAQ: MASI) has introduced Sleep Halo™, an advanced sleep analysis feature for the Masimo W1® Sport wearable. Sleep Halo uses 70,000+ daily measurements of continuous pulse oximetry data and advanced AI to provide detailed insights into sleep quality, including duration, sleep stages, and desaturation episodes. Users can view these insights and a Sleep Halo score on the Masimo Health app. This technology will also be featured in future Masimo wearables, such as the Masimo Freedom™ Watch and Band. Masimo W1 Sport owners can update their firmware and app to access Sleep Halo.

Masimo (NASDAQ: MASI) has announced a collaboration with Cleveland Clinic to enhance hospital remote patient monitoring (RPM) through the integration of Masimo’s Hospital Automation™ platform with Cleveland Clinic’s critical care (eHospital) and non-critical care (eCMU) central monitoring platforms. The partnership aims to improve clinical decision support and situational awareness, including predictive analytics and AI-based algorithms for cardiac care. Cleveland Clinic's programs have demonstrated success in reducing patient mortality and ICU stays. The collaboration will also develop new tools for early detection of adverse events, leveraging Masimo’s Halo engine technology.

Masimo has released an investor presentation detailing their innovation-driven strategy aimed at boosting growth and expanding margins. The company emphasizes its strong history of innovation under the leadership of Joe Kiani, aiming to double adjusted EPS to approximately $8 by 2029. The presentation also warns against Politan's attempt to take control of the company without paying a premium or offering a clear operational plan, claiming it poses a significant risk to shareholder value. Masimo urges stockholders to vote for Joe Kiani and Christopher Chavez in the upcoming Annual Meeting on July 25, 2024, to protect their investments.

On June 24, 2024, Masimo (NASDAQ: MASI) achieved a significant legal victory with the dismissal of a patent infringement lawsuit filed by Wrist SP Biotech. The lawsuit, initially filed in August 2023, accused Masimo's pulse oximetry sensors of infringing U.S. Patent No. 11,331,015. The case was transferred from the Western District of Texas to the Central District of California, where detailed evidence from Masimo led to the dismissal with no payment. Masimo, represented by the legal team at Knobbe Martens, has seen a series of legal successes, including a permanent injunction against Sotera Wireless and Foxconn, and an import ban on Apple watches that infringed Masimo's technology. CEO Joe Kiani emphasized the company's respect for valid intellectual property and praised the legal team's efforts.

Masimo's Board of Directors has filed proxy materials and issued a letter to stockholders, urging them to vote for current board nominees Joe Kiani and Christopher Chavez on the GOLD proxy card in the upcoming Annual Meeting on July 25, 2024. The Board warns that giving control to Politan Capital Management could jeopardize Masimo's innovation and growth. Masimo highlights its strong track record, ongoing organic growth, and plans for margin expansion. The Board criticizes Politan's obstructive behavior, which they believe threatens Masimo's future and operational stability. For more information, visit ProtectMasimosFuture.com.

Masimo (NASDAQ: MASI) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, at 8:00 a.m. Eastern Time.

A live webcast of their presentation will be available on the Masimo website, with a replay accessible afterward.

Masimo (NASDAQ: MASI) has announced a partnership with Mobilize Recovery to support the Mobilize Recovery 2024 bus tour, starting September 20th in Los Angeles. The tour aims to raise awareness and support communities in combating the opioid epidemic and improving addiction recovery. Masimo will feature two key innovations: the Opioid Halo™, an FDA-cleared monitoring solution for opioid-induced respiratory depression, and Bridge™, a non-surgical device for reducing opioid withdrawal symptoms. This initiative is part of a broader effort to prevent overdoses and enhance recovery outcomes across the U.S.